Groups issue statement on ethical use of AI in radiology

Groups issue statement on ethical use of AI in radiology

Artificial intelligence has tremendous potential for increasing the efficiency and accuracy of radiology. However, the technology also has “inherent pitfalls and biases” that must be addressed. That’s the contention of the American College of Radiology, European Society of Radiology, Radiological Society of North America, Society for Imaging Informatics in […] Click here to view original[…]

Cancer doctors offer key takeaways from American Society of Clinical Oncology conference

Another frontier in PARP inhibition: Understanding who won’t benefit

At the 2019 Congress of the European Society of Medical Oncology, PARP inhibitors continued their victory march. With the success of the PAOLA-1 trial, reported in Friday’s plenary session, as well as the PRIMA and VELIA/GOG-3005 trials, “we’ve got new front-line data that really introduces a paradigm shift into […] Click here to view original[…]

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor

SAN DIEGO, CA, USA I September 30, 2019 I Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for TPX-0046, a novel therapy […] Click here to view original[…]

Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy

TOKYO, Oct. 1, 2019 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier United States-based laboratory facility for next-generation biotech start-ups. This initiative, combined with the more […] Click here to view original[…]

Sunstone announce new investment in immuno-oncology company STipe Therapeutics

Sunstone announce new investment in immuno-oncology company STipe Therapeutics Copenhagen, 30 September 2019 – Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first in class drugs modulating the […] Click here to view original[…]

Blood test could detect more than 20 different types of cancer including pancreatic, ovarian and breast as scientists find it is 99.4% accurate

Blood test could detect more than 20 different types of cancer including pancreatic, ovarian and breast as scientists find it is 99.4% accurate

A new blood test could pick up on more than 20 different types of cancer, research suggests. Harvard University scientists created a test that looks for genetic changes associated with the development of tumours. When tried on nearly 3,600 blood samples, it correctly identified cancer patients in 99.4 per […] Click here to view original[…]

ESMO: Pfizer eyes commercial scale-up as Array colorectal cancer combo hits its marks

ESMO: Pfizer eyes commercial scale-up as Array colorectal cancer combo hits its marks

Pfizer presented data Monday at the ESMO annual meeting in Barcelona. (Pfizer) BARCELONA—Positive new colorectal cancer data has Pfizer envisioning a launch for its newly acquired Array meds. And the company is getting prepared. Monday at the European Society for Medical Oncology annual meeting, the New York drugmaker presented […] Click here to view original[…]

Give Patients a Voice in Myeloma Treatment Planning

Give Patients a Voice in Myeloma Treatment Planning

When treatment planning or conducting clinical trials for patients with multiple myeloma, it is crucial to include the patient and caregivers’ preferences, especially as more drug options become available in this space, said Noopur Raje, MD , director of the Center for Multiple Myeloma at Massachusetts General Hospital. “With […] Click here to view original[…]

Two phase 3 studies show efficacy of blinatumomab over chemotherapy for pediatric leukemia

Two phase 3 studies show efficacy of blinatumomab over chemotherapy for pediatric leukemia

Blinatumomab significantly extended EFS compared with conventional consolidation chemotherapy among children with high-risk B-cell acute lymphoblastic leukemia in first relapse, according to results of a prespecified interim analysis of the phase 3 20120215 study reported by the agent’s manufacturer. Blinatumomab (Blincyto, Amgen) — a bispecific CD19-directed CD3 T cell […] Click here to view original[…]

Pfizer expands real-world data collaboration with Flatiron Health

Pfizer expands real-world data collaboration with Flatiron Health

Pfizer has expanded its collaboration with oncology software provider Flatiron Health to integrate and increase the application of real-world data further in its development of targeted cancer drugs. Image: Pfizer, Flatiron Health expand real-world data collaboration to cover oncology. Photo: courtesy of Coolcaesar/Wikipedia.org. As per the agreement terms, Pfizer […] Click here to view original[…]

Could even more cancer patients benefit from PARP inhibitors?

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

THOUSAND OAKS, Calif., Sept. 24, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN ) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety […] Click here to view original[…]